Literature DB >> 28247266

Rucaparib: First Global Approval.

Yahiya Y Syed1.   

Abstract

Rucaparib (Rubraca™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncology, Inc. (Boulder, CO, USA) for the treatment of solid tumours. It has been approved in the USA as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. A marketing authorization application for rucaparib for the same indication has been submitted to the European Medicines Agency. Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer. This article summarizes the milestones in the development of rucaparib leading to this first approval for ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28247266     DOI： 10.1007/s40265-017-0716-2

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  22 in total

1.  The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias.

Authors:  Maria Vittoria Verga Falzacappa; Chiara Ronchini; Mario Faretta; Ilaria Iacobucci; Andrea Ghelli Luserna Di Rorà; Giovanni Martinelli; Lüder Hinrich Meyer; Klaus-Michael Debatin; Stefania Orecchioni; Francesco Bertolini; Pier Giuseppe Pelicci
Journal:  Mol Cancer Ther       Date:  2015-02-09       Impact factor: 6.261

2.  INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.

Authors:  Ying Sun; Huan Ding; Xinguang Liu; Xiaoqing Li; Li Li
Journal:  Tumour Biol       Date:  2014-01-14

3.  Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Authors:  Junko Murai; Shar-Yin N Huang; Amèlie Renaud; Yiping Zhang; Jiuping Ji; Shunichi Takeda; Joel Morris; Beverly Teicher; James H Doroshow; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2013-12-19       Impact factor: 6.261

4.  Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.

Authors:  Letizia Porcelli; Anna E Quatrale; Paola Mantuano; Maria G Leo; Nicola Silvestris; Jean F Rolland; Enza Carioggia; Marco Lioce; Angelo Paradiso; Amalia Azzariti
Journal:  Mol Oncol       Date:  2012-10-29       Impact factor: 6.603

Review 5.  Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.

Authors:  Zachary B Jenner; Anil K Sood; Robert L Coleman
Journal:  Future Oncol       Date:  2016-04-18       Impact factor: 3.404

6.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Authors:  Elizabeth M Swisher; Kevin K Lin; Amit M Oza; Clare L Scott; Heidi Giordano; James Sun; Gottfried E Konecny; Robert L Coleman; Anna V Tinker; David M O'Malley; Rebecca S Kristeleit; Ling Ma; Katherine M Bell-McGuinn; James D Brenton; Janiel M Cragun; Ana Oaknin; Isabelle Ray-Coquard; Maria I Harrell; Elaina Mann; Scott H Kaufmann; Anne Floquet; Alexandra Leary; Thomas C Harding; Sandra Goble; Lara Maloney; Jeff Isaacson; Andrew R Allen; Lindsey Rolfe; Roman Yelensky; Mitch Raponi; Iain A McNeish
Journal:  Lancet Oncol       Date:  2016-11-29       Impact factor: 41.316

7.  Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.

Authors:  Hsiao-Ching Chuang; Naval Kapuriya; Samuel K Kulp; Ching-Shih Chen; Charles L Shapiro
Journal:  Breast Cancer Res Treat       Date:  2012-06-08       Impact factor: 4.872

8.  The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.

Authors:  Majid Ali; Marzieh Kamjoo; Huw D Thomas; Suzanne Kyle; Ivanda Pavlovska; Muhammed Babur; Brian A Telfer; Nicola J Curtin; Kaye J Williams
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

9.  NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.

Authors:  J E Hunter; E Willmore; J A E Irving; Z Hostomsky; S J Veuger; B W Durkacz
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

10.  Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.

Authors:  Yvette Drew; Jonathan Ledermann; Geoff Hall; Daniel Rea; Ros Glasspool; Martin Highley; Gordon Jayson; Julieann Sludden; James Murray; David Jamieson; Sarah Halford; Gary Acton; Zoe Backholer; Raffaella Mangano; Alan Boddy; Nicola Curtin; Ruth Plummer
Journal:  Br J Cancer       Date:  2016-03-22       Impact factor: 7.640
View more
  25 in total

1.  Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

Authors:  Allison W Kurian; Kevin C Ward; Nadia Howlader; Dennis Deapen; Ann S Hamilton; Angela Mariotto; Daniel Miller; Lynne S Penberthy; Steven J Katz
Journal:  J Clin Oncol       Date:  2019-04-09       Impact factor: 44.544

Review 2.  Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.

Authors:  Yanxin Lu; Yang Liu; Ying Pang; Karel Pacak; Chunzhang Yang
Journal:  Pharmacol Ther       Date:  2018-04-03       Impact factor: 12.310

Review 3.  The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.

Authors:  Martina Pagliuca; Carlo Buonerba; Karim Fizazi; Giuseppe Di Lorenzo
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

4.  Loss of the p12 subunit of DNA polymerase delta leads to a defect in HR and sensitization to PARP inhibitors.

Authors:  Sufang Zhang; Hsiao Hsiang Chao; Xiaoxiao Wang; Zhongtao Zhang; Ernest Y C Lee; Marietta Y W T Lee
Journal:  DNA Repair (Amst)       Date:  2018-11-13

5.  An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Authors:  Nicholas Pulliam; Fang Fang; Ali R Ozes; Jessica Tang; Adeoluwa Adewuyi; Harold Keer; John Lyons; Stephen B Baylin; Daniela Matei; Harikrishna Nakshatri; Feyruz V Rassool; Kathy D Miller; Kenneth P Nephew
Journal:  Clin Cancer Res       Date:  2018-04-03       Impact factor: 12.531

Review 6.  PARkinson's: From cellular mechanisms to potential therapeutics.

Authors:  Zsofia Lengyel-Zhand; Laura N Puentes; Robert H Mach
Journal:  Pharmacol Ther       Date:  2021-08-12       Impact factor: 12.310

Review 7.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

Review 8.  Update on PARP Inhibitors in Breast Cancer.

Authors:  Alexandra S Zimmer; Mitchell Gillard; Stanley Lipkowitz; Jung-Min Lee
Journal:  Curr Treat Options Oncol       Date:  2018-04-11

9.  Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.

Authors:  Britta Vormoor; Yvonne T Schlosser; Helen Blair; Abhishek Sharma; Sarah Wilkinson; David R Newell; Nicola Curtin
Journal:  Oncotarget       Date:  2017-09-28

Review 10.  Advances in ovarian cancer therapy.

Authors:  Alexander J Cortez; Patrycja Tudrej; Katarzyna A Kujawa; Katarzyna M Lisowska
Journal:  Cancer Chemother Pharmacol       Date:  2017-12-16       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.